BRIEF-Alzamend Neuro Announces Full Data Set From Its Nonclinical Study

Reuters11-19 21:23

Nov 19 (Reuters) - Alzamend Neuro Inc :

* ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM ITS NONCLINICAL STUDY: COMPARING BRAIN AND PLASMA LITHIUM EXPOSURES BETWEEN AL001 AND LITHIUM CARBONATE IN ALZHEIMER’S TRANSGENIC MICE

* ALZAMEND NEURO INC: AT A LOW DOSE, AL001 EVIDENCED CONSISTENTLY HIGHER LITHIUM CONCENTRATIONS THAN LITHIUM CARBONATE WITHIN CRITICAL BRAIN REGIONS

* ALZAMEND NEURO INC: BOTH TREATMENTS HAD NO NEGATIVE IMPACT ON MICE'S BODY WEIGHT OR CLINICAL SIGNS DURING TREATMENT PERIOD

* ALZAMEND NEURO INC: AL001 SHOWED LOWER PLASMA LITHIUM LEVELS THAN LITHIUM CARBONATE, REDUCING RISK OF ADVERSE SYSTEMIC EFFECTS

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484941879?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-19 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484941879","market":"us","top_or_hot":-1,"title":"BRIEF-Alzamend Neuro Announces Full Data Set From Its Nonclinical Study","media":"Reuters","content":"<html><body><p>Nov 19 (Reuters) - Alzamend Neuro Inc   :</p><p>   * ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM ITS NONCLINICAL STUDY: COMPARING BRAIN AND PLASMA LITHIUM EXPOSURES BETWEEN AL001 AND LITHIUM CARBONATE IN ALZHEIMER’S TRANSGENIC MICE</p><p>   * ALZAMEND NEURO INC: AT A LOW DOSE, AL001 EVIDENCED CONSISTENTLY HIGHER LITHIUM CONCENTRATIONS THAN LITHIUM CARBONATE WITHIN CRITICAL BRAIN REGIONS</p><p>   * ALZAMEND NEURO INC: BOTH TREATMENTS HAD NO NEGATIVE IMPACT ON MICE'S BODY WEIGHT OR CLINICAL SIGNS DURING TREATMENT PERIOD</p><p>   * ALZAMEND NEURO INC: AL001 SHOWED LOWER PLASMA LITHIUM LEVELS THAN LITHIUM CARBONATE, REDUCING RISK OF ADVERSE SYSTEMIC EFFECTS</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Alzamend Neuro Announces Full Data Set From Its Nonclinical Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Alzamend Neuro Announces Full Data Set From Its Nonclinical Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nov 19 (Reuters) - Alzamend Neuro Inc   :   * ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM ITS NONCLINICAL STUDY: COMPARING BRAIN AND PLASMA LITHIUM EXPOSURES BETWEEN AL001 AND LITHIUM CARBONATE IN ...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALZN","symbol_name":"Alzamend Neuro, Inc","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2484941879","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484941879","pubTimestamp":1732022609,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Nov 19  - Alzamend Neuro Inc   :   * ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM ITS NONCLINICAL STUDY: COMPARING BRAIN AND PLASMA LITHIUM EXPOSURES BETWEEN AL001 AND LITHIUM CARBONATE IN ALZHEIMER’S TRANSGENIC MICE   * ALZAMEND NEURO INC: AT A LOW DOSE, AL001 EVIDENCED CONSISTENTLY HIGHER LITHIUM CONCENTRATIONS THAN LITHIUM CARBONATE WITHIN CRITICAL BRAIN REGIONS   * ALZAMEND NEURO INC: BOTH TREATMENTS HAD NO NEGATIVE IMPACT ON MICE'S BODY WEIGHT OR CLINICAL SIGNS DURING TREATMENT PERIOD   * ALZAMEND NEURO INC: AL001 SHOWED LOWER PLASMA LITHIUM LEVELS THAN LITHIUM CARBONATE, REDUCING RISK OF ADVERSE SYSTEMIC EFFECTSSource text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALZN":"Alzamend Neuro, Inc","BK4539":"次新股","BK4139":"生物科技"},"translate_title":"简介-Alzamend Neuro公布其非临床研究的完整数据集","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALZN":1},"content_text":"Nov 19 (Reuters) - Alzamend Neuro Inc   :   * ALZAMEND NEURO ANNOUNCES FULL DATA SET FROM ITS NONCLINICAL STUDY: COMPARING BRAIN AND PLASMA LITHIUM EXPOSURES BETWEEN AL001 AND LITHIUM CARBONATE IN ALZHEIMER’S TRANSGENIC MICE   * ALZAMEND NEURO INC: AT A LOW DOSE, AL001 EVIDENCED CONSISTENTLY HIGHER LITHIUM CONCENTRATIONS THAN LITHIUM CARBONATE WITHIN CRITICAL BRAIN REGIONS   * ALZAMEND NEURO INC: BOTH TREATMENTS HAD NO NEGATIVE IMPACT ON MICE'S BODY WEIGHT OR CLINICAL SIGNS DURING TREATMENT PERIOD   * ALZAMEND NEURO INC: AL001 SHOWED LOWER PLASMA LITHIUM LEVELS THAN LITHIUM CARBONATE, REDUCING RISK OF ADVERSE SYSTEMIC EFFECTSSource text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484941879"}